Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 16/20 | 0.48 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755691 | 0.86 | NPSR1 (0.41) | LIPGMITFPKMHTTRAB9A | |
| SCHEMBL752105 | 0.80 | LIPG (0.50) | LIPGLIPCNPSR1 | |
| SCHEMBL753666 | 0.77 | LIPG (0.47) | LIPGLIPCHTT | |
| SCHEMBL765745 | 0.77 | LIPG (0.34) | LIPGLIPC | |
| SCHEMBL751973 | 0.76 | NPSR1 (0.50) | MITFPKMHTTRAB9ANPSR1 | |
| SCHEMBL27606176 | 0.74 | NPSR1 (0.48) | MITFPKMHTTRAB9ANPSR1 | |
| SCHEMBL752899 | 0.74 | LIPG (0.51) | LIPGLIPC | |
| SCHEMBL754205 | 0.72 | LIPG (0.47) | LIPGLIPC | |
| SCHEMBL751203 | 0.72 | LIPG (0.50) | LIPGLIPCRAB9ANPSR1 | |
| SCHEMBL2778238 | 0.72 | LIPG (0.47) | LIPGLIPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-4651717-A1 | COMPOUNDS FOR INCREASING FROST TOLERANCE IN PLANTS | VIB VZW (BE) | 2025-11-26 | — | — | EP | claimed |
| US-12410174-B1 | Small molecular inhibitors of sting signaling compositions and methods of use | TYERELL IMMUNOTHERAPEUTICS INC (US) | 2025-09-09 | — | — | US | claimed |
| CN-120049017-A | Org/ZnSO4Electrolyte, preparation method thereof and application of electrolyte in secondary battery | 同济大学 | 2025-05-27 | — | — | CN | claimed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-115298170-B | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118696036-A | PARP1 inhibitors | 突触活化疗法股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118507836-B | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| WO-2002012242-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2002-02-14 | — | — | WO | claimed |
| CN-1284165-A | Method and reagents for quantification of solid-phase reactions using fluorine NMR | AVENTISS PHARMACEUTICAL PRODUC (US) | 2001-02-14 | — | — | CN | claimed |
| EP-1044364-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | Aventis Pharmaceuticals Products Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | claimed |
| US-5874444-A | CONTROLLING CELL AGING | GERON CORPORATION (US) | 1999-02-23 | — | — | US | claimed |
| EP-0696270-B1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 1998-11-04 | — | — | EP | claimed |
| US-5811454-A | 3-FLUOROBENZAMIDES WITH NITROGEN MUSTARD GROUPS; ANTICARCINOGENIC AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-09-22 | — | — | US | claimed |
| JP-H08509490-A | — | — | 1996-10-08 | — | — | JP | claimed |
| EP-0696270-A1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-02-14 | — | — | EP | claimed |
| WO-1994025429-A1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410174-B1 | Small molecular inhibitors of sting signaling compositions and methods of use | STING1, IRF3, MAVS | LIPG 1425/4885LIPC 2706/4885MITF 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.